What Has Been The Evolution of the Aptamers Market in Recent Years?
The aptamers market has seen considerable growth due to a variety of factors.
• The market size of aptamers has significantly escalated in the preceding years. Projection indicates an increase from $2.65 billion in 2024 to $3.28 billion in 2025, with a compound annual growth rate (CAGR) of 23.6%. The previous growth can be credited to the demand for high-specificity binders, their therapeutic potential, an upswing in personalized medicine, applications in various therapeutic areas, alternatives to antibodies, and diagnostic point-of-care (POC) devices.
What Is the Forecasted Market Size and Growth Rate for The Aptamers Template Market?
The Aptamers market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipations are high for a significant expansion in the aptamers market in the upcoming years, with projections indicating a growth up to $8.03 billion by 2029, experiencing a compound annual growth rate (CAGR) of 25.1%.
Several factors are likely to drive this growth during the forecasted timeframe, including escalating investments in life sciences, advances in drug development, expanded cancer research, swift detection in critical situations, refined aptamer selection procedures, and supportive regulations. The forecast period is also likely to witness notable trends such as progress in selex technology, raising applications in diagnostics, increased funding in aptamer research, integration of technology with nanotechnology, and initiatives aimed at enhancing awareness and education.
What Factors Are Driving Growth In The Aptamers Market?
The aptamers market is anticipated to expand due to the rising occurrence of chronic respiratory diseases. A chronic respiratory disease results in the swelling and constricting of the airways, often accompanied by the excess production of mucus, hindering respiration and leading to symptoms like coughing, breathlessness, and wheezing upon exhalation. Aptamers play a critical role in identifying the respiratory syncytial virus (RSV), enabling early detection of illness and intervention. For instance, data from the Australian Institute of Health and Welfare in June 2024 illustrates that COPD made up 3.6% of the total disease load and was associated with 50% of the disease burden of respiratory conditions in 2023. In 2022, COPD led to 7,691 deaths or 29.6 per 100,000 population, equating to 4.0% of all fatalities in Australia. Consequently, the escalating incidence of chronic respiratory diseases is contributing to the aptamers market's growth.
What Are The Main Segments Of The Global Aptamers Market?
The aptamers market covered in this report is segmented –
1) By Type: DNA Aptamers, XNA Aptamers, RNA Aptamers
2) By Technology: SELEX, X Aptamer, Maras Technique
3) By Application: Therapeutics Development, Research and Development, Diagnostic, Other Applications
4) By End User: Pharmaceutical And Biotechnology Companies, Academic And Government Research Institutes, Cathode-Ray Oscilloscope, Other End Users
Subsegments:
1) By DNA Aptamers: Single-Stranded DNA (ssDNA) Aptamers, Double-Stranded DNA (dsDNA) Aptamers
2) By XNA Aptamers: Peptide Nucleic Acid (PNA) Aptamers, Locked Nucleic Acid (LNA) Aptamers, Glycyl Nucleic Acid (GNA) Aptamers
3) By RNA Aptamers: Small Interfering RNA (siRNA) Aptamers, Short Hairpin RNA (shRNA) Aptamers, Long Non-Coding RNA (lncRNA) Aptamers
Pre-Book The Aptamers Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Aptamers Market?
Technological advancements are emerging as a significant trend in the aptamers market. Top firms in the sector are integrating new technologies, for instance, artificial DNA aptamers, made with flexible and continuous technology, to maintain their market dominance. To illustrate, in August 2023, Izervay gained FDA approval for the treatment of geographic atrophy linked to age-related macular degeneration. Izervay brings a new approach to managing the progression of geographic atrophy, giving hope to patients affected by this severe form of macular degeneration. The treatment's goal is to slow the attrition of retinal cells correlated with the disease, marking noteworthy progress in vision care.
Who Are the Key Players In The Aptamers Market?
Major companies operating in the aptamers market include:
• Aptamer Group Limited
• SomaLogic Inc.
• Aptamer Sciences Inc.
• Aptagen LLC
• NeoVentures Biotechnology Inc.
• Aptus Biotech
• Base Pair Biotechnologies Inc.
• AMS Biotechnology Ltd.
• Vivonics Inc.
• TriLink Biotechnologies LLC
• Noxxon Pharma SE
• AM Biotechnologies LLC
• Raptamer Discovery Group
• Kaneka Corporation
• Novaptech Inc.
• Maravai Lifesciences Inc.
• Bio-Techne Corporation
• Creative Biolabs Inc.
• IBA Lifesciences GmbH
• Aptabharat Innovations Pvt. Ltd.
• Profacgen Biotech Inc.
• Medi GmbH & Co. KG
• Pure Biologics Sp. z o.o.
• Oak BioSciences Inc.
• Ophthotech Corporation
• Novartis AG
• NeoNeuro SAS
• CAGE Bio Inc.
• TAGCyx Biotechnologies Inc.
• AstraZeneca PLC
• GlyTech Inc.
• GC Biopharma Corp.
• Achiko AG
• Agilent Technologies Inc.
• IVERIC bio Inc.
What Is The Most Dominant Region In The Aptamers Market?
North America was the largest region in the aptamers market in 2024. The regions covered in the aptamers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
